ライフサイエンスコーパス: pyridoxine

1 id, biotin, folate, riboflavin, thiamin, and pyridoxine).

2 the NADPH-mediated reduction of pyridoxal to pyridoxine.

3 quitin deficiency and are then responsive to pyridoxine.

4 ve seizures, but who responded clinically to pyridoxine.

5 ptom-free on occasional phlebotomy and daily pyridoxine.

6 tagonistic effect on the utilization of free pyridoxine.

7 e and E4P dehydrogenases are auxotrophic for pyridoxine.

8 r 3 days with concomitant metoclopramide and pyridoxine.

9 dietary B-vitamins thiamine, riboflavin and pyridoxine.

10 onosaccharide sugars, manganese, uridine, or pyridoxine.

11 grade 2 or higher HFS in patients receiving pyridoxine.

12 symptoms that are treatable with PLP and/or pyridoxine.

13 y combining it with the vitamin B6 precursor pyridoxine.

14 atients who responded and did not respond to pyridoxine.

15 n seizures that to respond to treatment with pyridoxine.

16 es was observed after 28 d of treatment with pyridoxine.

17 formulation (n = 1827), containing 25 mg of pyridoxine, 0.4 mg of cobalamin, and 2.5 mg of folic aci

18 We set out to turn pyridoxine (1a) into a catalytic chain-breaking and hydr

19 tients were randomized to receive concurrent pyridoxine (200 mg) or placebo daily for a maximum of 8

20 They were given pyridoxine (350 mg/kg, i.p.) on 2 successive days (0 and

21 ng studies of the nutritional utilization of pyridoxine 5'-beta-D-glucoside, a major form of vitamin

22 vitamin B(6) pools found the high-levels of pyridoxine 5'-phosphate (PNP) in the two yggS mutants.

23 sphate-dependent pathway, whose last step is pyridoxine 5'-phosphate (PNP) oxidation to PLP, catalyze

24 B6 include pyridoxamine 5'-phosphate (PMP), pyridoxine 5'-phosphate (PNP), and the corresponding non

25 that leads productively to the formation of pyridoxine 5'-phosphate (PNP).

26 BS before and after a 30 min incubation with pyridoxine 5'-phosphate (PNP).

27 due to an approximately 192-fold decrease in pyridoxine 5'-phosphate affinity and an approximately 4.

28 the concentration-dependent accumulation of pyridoxine 5'-phosphate and pyridoxamine 5'-phosphate (P

29 ridoxal 5'-phosphate by the FMN oxidation of pyridoxine 5'-phosphate forming FMNH(2) and H(2)O(2).

30 Pyridoxine 5'-phosphate hydrolase activity (pH 10) in cu

31 sistent significant change in pyridoxine and pyridoxine 5'-phosphate levels.

32 herichia coli, PLP formation is catalyzed by pyridoxine 5'-phosphate oxidase (PNPO), a homodimeric FM

33 Mutations in pyridoxine 5'-phosphate oxidase are known to cause neona

34 Pyridoxine 5'-phosphate oxidase catalyzes the oxidation

35 Escherichia coli pyridoxine 5'-phosphate oxidase catalyzes the terminal s

36 e shown that in addition to the active site, pyridoxine 5'-phosphate oxidase contains a non-catalytic

37 orm of the Arabidopsis epimerase lacking the pyridoxine 5'-phosphate oxidase domain.

38 The crystal structure of pyridoxine 5'-phosphate oxidase from E. coli with one or

39 nding the pathophysiological consequences of pyridoxine 5'-phosphate oxidase mutations.

40 n with a combination of pyridoxal kinase and pyridoxine 5'-phosphate oxidase.

41 duct inhibition of both pyridoxal kinase and pyridoxine 5'-phosphate oxidase.

42 being fused to the vitamin B6 salvage enzyme pyridoxine 5'-phosphate oxidase.

43 We report the 1.96 A crystal structure of pyridoxine 5'-phosphate synthase (PdxJ) in complex with

44 phosphate oxidase catalyzes the oxidation of pyridoxine 5'-phosphate to pyridoxal 5'-phosphate, the a

45 icipate in formation of the pyridine ring of pyridoxine 5'-phosphate.

46 yridoxamine) kinase (SOS4) and pyridoxamine (pyridoxine) 5' phosphate oxidase (PDX3), have been ident

47 In particular, pyridoxine- 5'-phosphate oxidase (PNPO), the rate-limiti

48 in the mammalian nutritional utilization of pyridoxine-5'-beta-D-glucoside (PNG) is the intestinal h

49 ulation (n = 1853), containing 200 microg of pyridoxine, 6 microg of cobalamin and 20 microg of folic

50 Beta-Glucosides of pyridoxine (a) are prevalent in plant-derived foods, (b)

51 The cyclic pyridoxine-alpha4, 5-monophosphate, compound 2 (MRS 2219

52 ral regions, where amino acids, tocopherols, pyridoxine and 4-aminobenzoic acid show intense emission

53 dual-encapsulated nanoparticles loaded with pyridoxine and cyanocobalamin (PC-PP NPs).

54 commend consideration of treatment with both pyridoxine and folinic acid for patients with alpha-AASA

55 g phenotypes identified mutations in biotin, pyridoxine and niacin biosynthetic pathways.

56 catalyses the phosphorylation of pyridoxal, pyridoxine and pyridoxamine to their 5' phosphates and p

57 tion as a PL kinase, in vitro application of pyridoxine and pyridoxamine, but not PL, partially rescu

58 here was no consistent significant change in pyridoxine and pyridoxine 5'-phosphate levels.

59 le, phenobarbital, chlorpheniramine maleate, pyridoxine and riboflavin.

60 Both pyridoxine and serine synergistically rescued embryonic

61 cts of thiamin, especially in medium lacking pyridoxine and with high sugar concentrations.

62 aining 0.45 mg vitamin B-6 (2.66 micromol as pyridoxine) and 30 micromol carnitine for 92 d.

63 involved in the biosynthesis of vitamins B6 (pyridoxine) and B1 (thiamin).

64 es and the intake of folic acid, vitamin B6 (pyridoxine), and vitamin B12 (cobalamin).

65 roup vitamins alone (1 mg folic acid, 7.2 mg pyridoxine, and 0.02 mg cyanocobalamin), antioxidant vit

66 exercise their primary functions in serine, pyridoxine, and histidine biosynthesis, they also have c

67 utrient metabolism; and folate, vitamin B12, pyridoxine, and riboflavin play important roles in the r

68 ry high intakes of vitamins A and D, niacin, pyridoxine, and selenium have produced adverse effects.

69 efficiency with pyridoxal, pyridoxamine and pyridoxine, and that ginkgotoxin is an effective pseudo

70 y Allowances of thiamin, riboflavin, niacin, pyridoxine, and vitamin B-12.

71 s of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines, and metoclopramide were asso

72 r HFS occurred in 33 patients (31.4%) in the pyridoxine arm vs 39 patients (37.1%) in the placebo arm

73 imaging screen to identify nicotinamide and pyridoxine as promoters of MuSC function.

74 from neuropathy induced by intoxication with pyridoxine assessed by electrophysiological (foot sensor

75 rmed by complementation of two C. nicotianae pyridoxine auxotrophs not mutant in PDX1.

76 lacement of PDX2 in C. nicotianae results in pyridoxine auxotrophy.

77 f B vitamins (thiamin B(1), riboflavin B(2), pyridoxine B(6), biotin B(7), and cobalamin B(12)) were

78 in (B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), biotin (B7) and folates (B9) were deter

79 m NSCLC by the combined regimen of CDDP plus pyridoxine became resistant against subcutaneous rechall

80 at hydrolyzed aryl beta-D-glycosides but not pyridoxine beta-D-glucoside.

81 oside hydrolase, that efficiently hydrolyzed pyridoxine beta-D-glucoside.

82 Wide variations in pyridoxine, beta-glucans and fermentable sugars levels w

83 d specificity beta-glucosidase 1460-fold and pyridoxine-beta-D-glucoside hydrolase 36,500-fold.

84 f lysosomal acid beta-glucosidase, inhibited pyridoxine-beta-D-glucoside hydrolase but not broad spec

85 Purified pyridoxine-beta-D-glucoside hydrolase did not hydrolyze

86 Pyridoxine-beta-D-glucoside hydrolase exhibited a pH opt

87 ound a previously unknown enzyme, designated pyridoxine-beta-D-glucoside hydrolase, that efficiently

88 nt differences were observed in the level of pyridoxine between the meat and vegetable-based varietie

89 that organisms encode either SOR1 or E. coli pyridoxine biosynthesis genes, but not both, suggesting

90 Although pyridoxine biosynthesis has been thoroughly examined in

91 there are two divergent pathways for de novo pyridoxine biosynthesis in nature.

92 wth, demonstrating that PDX1 is required for pyridoxine biosynthesis in planta.

93 eactions involved in biotin, ubiquinone, and pyridoxine biosynthesis in Z. mobilis were identified an

94 ion of a second gene in the newly identified pyridoxine biosynthesis pathway of archaebacteria, some

95 e vitamin B6 biosynthesis protein machinery, PYRIDOXINE BIOSYNTHESIS PROTEIN1.

96 The role of PDX2 in pyridoxine biosynthesis was confirmed by complementation

97 encoding an enzyme specifically required for pyridoxine biosynthesis.

98 as enabled us to define a second pathway for pyridoxine biosynthesis.

99 bacteria evolved with different pathways for pyridoxine biosynthesis?

100 Gene expression, PYRIDOXINE BIOSYNTHESIS1 (PDX1) accumulation, and leaf m

101 Some bacteria utilize the pdx pyridoxine biosynthetic pathway defined in Escherichia c

102 Supplementation of pyridoxine but not pyridoxal in the growth medium can pa

103 zures that did not respond to treatment with pyridoxine but responded to treatment with pyridoxal 5'-

104 e yeast were grown in high concentrations of pyridoxine, but a severe phenotype when grown in low con

105 The increase in nicotinamide and decrease in pyridoxine by curing salts and the decrease in both vita

106 hoxazole plus at least 12 weeks of isoniazid-pyridoxine (coformulated with trimethoprim-sulfamethoxaz

107 The novel pyridoxine compounds were found to inhibit azo-initiated

108 eration and germination reduced thiamine and pyridoxine concentrations (retentions ranging from 3.8 t

109 Experiments utilizing (13)C(4)-pyridoxine confirmed lower pyridox(am)ine 5'-phosphate o

110 Reducing the pyridoxine content of the culture medium significantly i

111 of both PLPHP homologs perturbs vitamin B6 (pyridoxine) content, inducing a PLP deficit accompanied

112 ancer Centre Singapore assessed whether oral pyridoxine could prevent the onset of grade 2 or higher

113 The chalcogen-containing pyridoxines could also mimic the action of the glutathio

114 ypersensitivity of the SLC25A38-CSA model to pyridoxine deficiency, a phenotype that is not shared wi

115 between the heme synthesis-related CSAs and pyridoxine deficiency.

116 Pyridoxine dependency is an uncommon but important cause

117 series suggested that clinical diagnosis of pyridoxine dependent epilepsy can be challenging because

118 Pyridoxine dependent epilepsy is a treatable condition w

119 Pyridoxine dependent epilepsy is diagnosed clinically bu

120 wn clinical disorders of GABA metabolism are pyridoxine dependent epilepsy, GABA-transaminase deficie

121 at mutations in the human ALDH7A1 gene cause pyridoxine-dependent and folic acid-responsive seizures.

122 use models of l-lysine catabolism disorders: pyridoxine-dependent epilepsy (ALDH7A1) and glutaric aci

123 Pyridoxine-dependent epilepsy (PDE) is a rare autosomal

124 study on urine from patients suffering from Pyridoxine-Dependent Epilepsy (PDE), currently diagnosed

125 uable information for the rapid diagnosis of pyridoxine-dependent epilepsy (PDE).

126 lities has been reported in individuals with pyridoxine-dependent epilepsy (PDE).

127 Pyridoxine-dependent epilepsy (PDE-ALDH7A1) is an inborn

128 iomarkers for the inborn error of metabolism pyridoxine-dependent epilepsy (PDE-ALDH7A1), which shows

129 patients with suspected or clinically proven pyridoxine-dependent epilepsy and to characterize furthe

130 Folinic acid-responsive seizures and pyridoxine-dependent epilepsy are two treatable causes o

131 o children from a consanguineous family with pyridoxine-dependent epilepsy revealed a homozygous nons

132 Pyridoxine-dependent epilepsy was recently shown to be d

133 seizures are identical to the major form of pyridoxine-dependent epilepsy.

134 We show here that children with pyridoxine-dependent seizures (PDS) have mutations in th

135 rve as a diagnostic marker for patients with pyridoxine-dependent seizures.

136 The most lipid-soluble pyridoxine derivative 20c was regenerable and could inhi

137 In vitro, CDDP and pyridoxine did not only cause synergistic killing of NSC

138 Pyridoxine did not significantly prevent or delay the on

139 -inflammatory inflammasome inhibiting lipid (pyridoxine dipalmitate) as a trojan horse.

140 other PN derivative that was identified as a pyridoxine disaccharide.

141 vere symptoms, 1 RCT (n = 60) suggested that pyridoxine-doxylamine combination taken preemptively red

142 tamines, metoclopramide (for mild symptoms), pyridoxine-doxylamine, and ondansetron (for moderate sym

143 For moderate symptoms, pyridoxine-doxylamine, promethazine, and metoclopramide

144 CDDP and pyridoxine exhibited hyperadditive therapeutic effects.

145 tent and antioxidant capacity, beta-glucans, pyridoxine, folates and silicon were quantified.

146 ms of the Reference Nutrient Intake (RNI) of pyridoxine for 6-9 months old infants, the complementary

147 timated total daily intake of riboflavin and pyridoxine from the consumption of commercial complement

148 the organisms with homologues to the E. coli pyridoxine genes, but are found in the same archaebacter

149 Pyridoxine given in large doses is thought to destroy se

150 the activity and its consequences regarding pyridoxine glucoside bioavailability are in progress.

151 ay comprising pyridoxine synthase (PDX1) and pyridoxine glutaminase (PDX2).

152 out in 1.0x10(-4)molkg(-1) thiamine HCl and pyridoxine HCl solutions.

153 0.25 and 0.35)molkg(-1) thiamine HCl(aq) and pyridoxine HCl(aq) solutions over temperature range (288

154 earlier in l-ascorbic acid, thiamine HCl and pyridoxine HCl.

155 in, niacinamide, d-calcium pantothenate, and pyridoxine HCl; 50 microg each of d-biotin and cyanocoba

156 in plasma in 10 men receiving a low (0.4 mg pyridoxine.HCl/d) or high (200 mg pyridoxine.HCl/d) vita

157 ow (0.4 mg pyridoxine.HCl/d) or high (200 mg pyridoxine.HCl/d) vitamin B-6 intake for 6 wk, in 10 hea

158 and after 28 d of supplementation with 10 mg pyridoxine hydrochloric acid/d.

159 le containing 40 mg of folic acid, 100 mg of pyridoxine hydrochloride (vitamin B6), and 2 mg of cyano

160 olic transformations of [3,4-14C] and [3H]C6-pyridoxine hydrochloride by tumor-bearing rats and tumor

161 were randomized to isoniazid, 300 mg/d, with pyridoxine hydrochloride for 12 months (n = 792) or rifa

162 ne-2-carboxaldehyde prepared from commercial pyridoxine hydrochloride.

163 before and after daily treatment with 40 mg pyridoxine hydrochloride.

164 andgrip before and after a local infusion of pyridoxine (i.e. vitamin B(6)) into the 'isolated' circu

165 lin, levetiracetam), hypothermia, magnesium, pyridoxine, immunotherapy, ketogenic diet, emergency neu

166 ts, suggesting a previously unknown role for pyridoxine in active oxygen resistance.

167 quantitative determination of riboflavin and pyridoxine in eight different complementary infant meal

168 spikes, which could be rescued by supplying pyridoxine in embryo water.

169 ntiquitin deficiency and a clinical trial of pyridoxine in infants and children with epilepsy across

170 ed remarkable concentrations of thiamine and pyridoxine in pistachios (57%, 79% of the recommended da

171 utative synergistic interaction of CDDP with pyridoxine in the treatment of an orthotopic mouse model

172 NSCLC cells treated with CDDP plus pyridoxine in vitro elicited a protective anticancer imm

173 s respond to pyridoxal phosphate rather than pyridoxine, including a rare form of neonatal epileptic

174 This study examined the effects of pyridoxine-induced somatosensory loss on automatic postu

175 Pyridoxine is converted into a P2-purinoceptor antagonis

176 We also found that pyridoxine is destroyed in the presence of singlet oxyge

177 energy drinks, such as taurine, niacin, and pyridoxine, is less well defined.

178 imics of the glutathione peroxidase enzymes, pyridoxine-like diselenides 6 and 11, carrying a 6-bromo

179 Thiamine, riboflavin, pyridoxine, lutein, zeaxanthin, beta-carotene and alpha-

180 with multisystem pathology, the response to pyridoxine may not be instant and obvious; and (iii) str

181 by high doses of folic acid, cobalamin, and pyridoxine may reduce progression of structural brain ch

182 ely, a component of Bendectin (most probably pyridoxine) may be important for normal heart developmen

183 that the combined regimen of cisplatin plus pyridoxine mediates immune-dependent antineoplastic effe

184 MC-1, a naturally occurring pyridoxine metabolite and purinergic receptor antagonist

185 borderline low in all family members and CSF pyridoxine metabolites were normal.

186 symmetric molecular constructs, in which two pyridoxine moieties are connected via sulfur-containing

187 starting under 3 months of age responding to pyridoxine (n = 8).

188 Treatment for pyridoxine-nonresponsive HCU involves lowering homocyste

189 to PLP supplementation, consistent with the pyridoxine-nonresponsive phenotype of the T257M mutation

190 la mutants defective for para-aminobenzoate, pyridoxine or l-threonine biosynthesis exhibit substanti

191 ency and severity of seizures in response to pyridoxine or pyridoxal 5'-phosphate.

192 Culturing cells with pyridoxine or pyridoxamine led to the concentration-depe

193 Supplementation of the growth media with pyridoxine or reintroduction of the wild-type PDX1 gene

194 ther pyridoxal (PL) or its related vitamers, pyridoxine (PN) and pyridoxamine (PM).

195 from food to identify nicotinamide (NAM) and pyridoxine (PN) as bioactive nutrients that stimulate Mu

196 Vitamin B6 in the form of pyridoxine (PN) is one of the most widespread pharmacolo

197 The bioavailability of the pyridoxal (PL), pyridoxine (PN), and pyridoxamine (PM) forms of vitamin

198 vulsant treatment but are well-controlled by pyridoxine (PN).

199 is of its beta-glucosidic bond that releases pyridoxine (PN).

200 pdrK encodes a pyridoxine (PN)/pyridoxal (PL)/pyridoxamine (PM) kinase

201 n of two major components of vitamin B6 i.e. pyridoxine (Py) and pyridoxal-5'-phosphate (PLP) using t

202 and inter-convertible pyridine-derivatives: pyridoxine, pyridoxal and pyridoxamine.

203 e reannotated ThiD, and B. subtilis ThiD has pyridoxine, pyridoxal, and pyridoxamine kinase activity

204 erized, however only two enzymes, pyridoxal (pyridoxine, pyridoxamine) kinase (SOS4) and pyridoxamine

205 This mutant had higher levels of pyridoxine, pyridoxamine, and pyridoxal 5'-phosphate tha

206 ependent of extracellular B(6) vitamer type (pyridoxine, pyridoxamine, or pyridoxal), intracellular p

207 dinium derivatives (pyridinoline, desmosine, pyridoxine, pyridoxamine, pyridoxal, pyridoxal-5'-phosph

208 and SALT OVERLY SENSITIVE4 (SOS4), encoding pyridoxine/pyridoxamine 5'-phosphate oxidase and pyridox

209 We also present data showing that pyridoxine quenches singlet oxygen at a rate comparable

210 190V mutant was identified in a patient with pyridoxine-refractory X-linked sideroblastic anemia, our

211 contain the minimum levels of riboflavin and pyridoxine required for the labelling declaration of the

212 omologs map to the region occupied by pdx-1 (pyridoxine requiring), a gene that has been known for se

213 In this study, pyridoxine-requiring mutants of N. crassa were found to

214 e pyridoxine unresponsive, patients who were pyridoxine responsive, and controls, respectively ( P =0

215 cant conversion of glycolate into glycine in pyridoxine responsive, but not in patients with PH1 who

216 The epilepsy was serine and pyridoxine responsive.

217 the G797A mutation is an important cause of pyridoxine-responsive CBS deficiency and demonstrate the

218 Five of the seven patients classified as pyridoxine-responsive contain the newly identified point

219 t sequencing of 29 unrelated indivduals with pyridoxine-responsive epilepsy identified four additiona

220 All probands were clinically pyridoxine-responsive.

221 It is possible that pyridoxine responsiveness in PNPO deficiency is affected

222 s and eight patients with PH1 (stratified by pyridoxine responsiveness) underwent a combined primed c

223 luate efficacy of new therapies, investigate pyridoxine responsiveness, and serve as a tool to furthe

224 obands suggest that iron overload suppresses pyridoxine responsiveness.

225 ant lacking the PROSC homolog (DeltaYggS) is pyridoxine sensitive; complementation with human PROSC r

226 tic trials of pyridoxal phosphate as well as pyridoxine should be considered early in the course of t

227 Treatment with pyridoxine significantly improved the epileptic phenotyp

228 s, anti-epileptic drugs, magnesium infusion, pyridoxine, steroids and immunotherapy, ketogenic diet,

229 PLP, having been resistant to treatment with pyridoxine, suggesting a defect of pyridox(am)ine 5'-pho

230 hese malformations persist despite postnatal pyridoxine supplementation and likely contribute to neur

231 ndicate the value of combined phlebotomy and pyridoxine supplementation in the management of XLSA pro

232 Pyridoxine supplementation increased the mean +/- SD pla

233 ell-documented response of XLSA mutations to pyridoxine supplementation, we also demonstrate the rela

234 d in higher hemoglobin concentrations during pyridoxine supplementation.

235 Treatments are limited to pyridoxine supplements and blood transfusions, offering

236 using a relatively simple pathway comprising pyridoxine synthase (PDX1) and pyridoxine glutaminase (P

237 In this study, an Arabidopsis pyridoxine synthase gene PDX1 was characterized and its

238 e the vitamin de novo employing two enzymes, pyridoxine synthase1 (PDX1) and PDX2.

239 the discovery that most organisms contain a pyridoxine synthesis gene not found in E. coli.

240 t shows no homology to previously identified pyridoxine synthesis genes identified in Escherichia col

241 tory occlusion were significantly less after pyridoxine than they were before.

242 menting the diet of rats with tryptophan and pyridoxine; the elevated brain serotonin levels had beha

243 Pyridoxine therapy had no effect in the proband, but in

244 with these mutations should be responsive to pyridoxine therapy.

245 was a worsening of symptoms on changing from pyridoxine to pyridoxal 5'-phosphate.

246 n endosperm revealed that endosperm supplies pyridoxine to the developing embryo.

247 Pyridoxine toxicity was manifest as deficits in simple a

248 lectrophysiological sequelae associated with pyridoxine toxicity.

249 ; 5-20 mg . kg-1 . d-1, s.c.) during chronic pyridoxine treatment largely attenuated the behavioral a

250 We aimed to assess the effect of pyridoxine treatment on B-6 vitamer and inflammatory mar

251 ECA reduced oxalate accumulation, similar to pyridoxine treatment that works in a small subset of PH1

252 nts diagnosed with CBS deficiency respond to pyridoxine treatment with a significant lowering of tHcy

253 rkers were preserved or even increased after pyridoxine treatment.

254 d and patient cohorts; however, vitamin B-6 (pyridoxine) treatment has mostly failed to improve infla

255 e development of a therapeutical approach to pyridoxine unresponsive homocystinuria.

256 and 0.79 (0.15) mmol/d in patients who were pyridoxine unresponsive, patients who were pyridoxine re

257 nsive, but not in patients with PH1 who were pyridoxine unresponsive.

258 Pyridoxine-unresponsive homocystinuria has lifelong impl

259 Pyridoxine (vitamin B6) is a cofactor required by numero

260 served proteins that have been implicated in pyridoxine (vitamin B6) metabolism in the filamentous fu

261 adult rats for 2-3 weeks with high doses of pyridoxine (vitamin B6) produced a profound propriocepti

262 We show that SOR1 is essential in pyridoxine (vitamin B6) synthesis in C. nicotianae and A

263 mine (dropped from the formulation in 1976), pyridoxine (vitamin B6)), was associated with a lower ri

264 ssant), as well as natural compounds such as pyridoxine (vitamin B6), cyanocobalamin (vitamin B12), a

265 ed into a single fixed-dose pill, along with pyridoxine (vitamin B6), that would be taken once per da

266 of restriction or supplementation of dietary pyridoxine (vitamin B6), the essential cofactor of ALAS2

267 of B complex vitamins (thiamine, riboflavin, pyridoxine), vitamin E (a, B, y, d tocopherols and tocot

268 of B complex vitamins (thiamine, riboflavin, pyridoxine), vitamin E (alpha, beta, gamma, delta tocoph

269 rients include thiamine, riboflavin, niacin, pyridoxine, vitamin B-12, vitamin D, vitamin K, calcium,

270 uced with pharmacologic doses of folic acid, pyridoxine, vitamin B12, or betaine, but further researc

271 Glycosylated forms of pyridoxine, vitamin D, niacin, pantothenate, and ribofla

272 ), pantothenate/vitamin B(5) (1.3-fold), and pyridoxine/vitamin B(6) (1.3-fold); indicating that feed

273 t pups cannot synthesise themselves, such as pyridoxine/vitamin B6, taurine, some essential amino aci

274 grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predict

275 Moreover, treatment with both DECA and pyridoxine was additive in reducing oxalate levels.

276 ety: i.e. a CH2OH group at the 4-position in pyridoxine was either condensed as a cyclic phosphate or

277 The intake of both riboflavin and pyridoxine was estimated to be mainly derived from the c

278 corresponding organic product (pyridoxal and pyridoxine) was -0.03 +/- 0.09.

279 py such as, for example, combined doxylamine/pyridoxine, which is not teratogenic and may be effectiv